Abstract 325P
Background
More patients are receiving immune checkpoint inhibitors (ICI) for advanced hepatocellular carcinoma (HCC). We aim to explore whether an association exists between the presence of irAE and the efficacy of ICI in advanced HCC.
Methods
We conducted a retrospective review of patients with advanced HCC who received ICIs between May 2015 - Nov 2018 at our centre. IrAE were graded according to the Common Terminology Criteria for Adverse Events v4.0. Response to ICI was evaluated based on RECIST v1.1 criteria.
Results
Of the 114 patients studied, median age was 67.3yrs (23.5-84.9) and 78 (89.7%) were male. 68.4% experienced irAE of any grade (n = 78), with 21.8% being grade 3-4 (n = 17). None were grade 5. Patients in the any-irAE group had comparable ORR and significantly higher DCR than the no-irAE group (23.4 vs 10.0%, p = 0.118 and 64.9 vs 30.0%, p = 0.001). Median PFS and OS in the any-irAE group were significantly longer than the no-irAE group (4.0 vs 1.4mths, p < 0.001 and 16.4 vs 3.3mths, p < 0.001, respectively). Comparing against the no-irAE group, the G1/2-irAE and G3/4-irAE groups had significantly longer median PFS (G1/2 (3.7mths) vs no irAE (1.4mths), p < 0.001; G3/4 (11.6mths) vs. no irAE (1.4mths), p = 0.001) and OS (G1/2 (14.5mths) vs no irAE (3.3mths), p < 0.001; G3/4 (20.9mths) vs. no irAE (3.3mths), p < 0.001). Multivariate analysis showed that the presence of irAE was associated with longer median PFS [HR: 0.52 (95% CI 0.31-0.90), p = 0.018] and OS [HR: 0.38 (95% CI 0.20-0.71), p = 0.003]. Table:
325P Cox regression analysis of the association between irAE and survival outcomes
Univariate hazard ratio (95% CI) | p-value | Multivariate hazard ratio* (95% CI) | p-value | |
---|---|---|---|---|
PFS | ||||
Any | 0.37 (0.23-0.59) | <0.001 | 0.52 (0.31-0.90) | 0.018 |
Hepatobiliary irAE | 0.75 (0.44-1.26) | 0.28 | ||
Skin irAE | 0.29 (0.18-0.46) | <0.001 | 0.32 (0.20-0.52) | <0.001 |
Gastrointestinal irAE | 0.76 (0.45-1.27) | 0.29 | ||
Endocrine irAE | 0.27 (0.08-0.91) | 0.035 | 0.34 (0.10-1.18) | 0.091 |
Lung irAE | 0.24 (0.06-0.97) | 0.046 | 0.29 (0.07-1.20) | 0.087 |
OS | ||||
Any | 0.27 (0.16-0.47) | <0.001 | 0.38 (0.20-0.71) | 0.003 |
Hepatobiliary irAE | 0.56 (0.28-1.12) | 0.10 | ||
Skin irAE | 0.28 (0.16-0.49) | <0.001 | 0.35 (0.19-0.64) | 0.001 |
Gastrointestinal irAE | 0.58 (0.29-1.15) | 0.12 | ||
Endocrine irAE | 0.36 (0.11-1.24) | 0.11 | ||
Lung irAE | 0.38 (0.09-1.61) | 0.19 |
Significant covariables in univariate analysis were included; for PFS: age category, bilirubin category; for OS: age category, albumin category, bilirubin category.
Conclusions
The presence of irAE in advanced HCC patients treated with ICI could possibly predict better response and survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S.P. Choo: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (self): Sirtex Medical; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lily; Advisory / Consultancy: Novartis; Advisory / Consultancy: Eisai; Advisory / Consultancy: Bayer; Advisory / Consultancy: Celgene; Advisory / Consultancy: Ipsen. D. Tai: Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Bayer; Advisory / Consultancy: Ipsen; Research grant / Funding (self): Sirtex. J. Lee: Advisory / Consultancy: Ipsen; Research grant / Funding (self): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract